Research and Development Service, John D. Dingell VA Medical Center, Detroit, Michigan, United States of America.
Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, United States of America.
PLoS One. 2020 Jan 24;15(1):e0227774. doi: 10.1371/journal.pone.0227774. eCollection 2020.
The list of pharmacological agents that can modify the gut microbiome or be modified by it continues to grow at a high rate. The greatest amount of attention on drug-gut microbiome interactions has been directed primarily at pharmaceuticals used to treat infection, diabetes, cardiovascular conditions and cancer. By comparison, drugs of abuse and addiction, which can powerfully and chronically worsen human health, have received relatively little attention in this regard. Therefore, the main objective of this study was to characterize how selected synthetic psychoactive cathinones (aka "Bath Salts") and amphetamine stimulants modify the gut microbiome. Mice were treated with mephedrone (40 mg/kg), methcathinone (80 mg/kg), methamphetamine (5 mg/kg) or 4-methyl-methamphetamine (40 mg/kg), following a binge regimen consisting of 4 injections at 2h intervals. These drugs were selected for study because they are structural analogs that contain a β-keto substituent (methcathinone), a 4-methyl group (4-methyl-methamphetamine), both substituents (mephedrone) or neither (methamphetamine). Mice were sacrificed 1, 2 or 7 days after treatment and DNA from caecum contents was subjected to 16S rRNA sequencing. We found that all drugs caused significant time- and structure-dependent alterations in the diversity and taxonomic structure of the gut microbiome. The two phyla most changed by drug treatments were Firmicutes (methcathinone, 4-methyl-methamphetamine) and Bacteriodetes (methcathinone, 4-methyl-methamphetamine, methamphetamine, mephedrone). Across time, broad microbiome changes from the phylum to genus levels were characteristic of all drugs. The present results signify that these selected psychoactive drugs, which are thought to exert their primary effects within the CNS, can have profound effects on the gut microbiome. They also suggest new avenues of investigation into the possibility that gut-derived signals could modulate drug abuse and addiction via altered communication along the gut-brain axis.
能够改变肠道微生物组或受其改变的药物种类持续快速增加。人们对药物-肠道微生物组相互作用的关注主要集中在用于治疗感染、糖尿病、心血管疾病和癌症的药物上。相比之下,在这方面,成瘾药物和滥用药物受到的关注相对较少,而这些药物会严重且长期地损害人类健康。因此,本研究的主要目的是描述选定的合成致幻苯丙胺类药物(又称“浴盐”)和苯丙胺类兴奋剂如何改变肠道微生物组。采用 binge 给药方案(4 次/2h),用以下药物对小鼠进行处理:氯胺酮(40mg/kg)、甲卡西酮(80mg/kg)、甲基苯丙胺(5mg/kg)或 4-甲基甲卡西酮(40mg/kg)。选择这些药物进行研究是因为它们是结构类似物,含有β-酮取代基(甲卡西酮)、4-甲基(4-甲基甲卡西酮)、两个取代基(氯胺酮)或都没有(甲基苯丙胺)。在治疗后 1、2 或 7 天处死小鼠,提取盲肠内容物的 DNA 进行 16S rRNA 测序。我们发现,所有药物都导致肠道微生物组的多样性和分类结构发生显著的时间和结构依赖性改变。受药物治疗影响最大的两个菌门是厚壁菌门(甲卡西酮、4-甲基甲卡西酮)和拟杆菌门(甲卡西酮、4-甲基甲卡西酮、甲基苯丙胺、氯胺酮)。随着时间的推移,从菌门到属水平的广泛微生物组变化是所有药物的特征。这些结果表明,这些被认为主要在中枢神经系统发挥作用的精神活性药物会对肠道微生物组产生深远影响。它们还提示人们可以通过研究肠道来源的信号是否可以通过改变沿肠道-大脑轴的通讯来调节药物滥用和成瘾,从而开辟新的研究途径。